Benign prostatic hyperplasia (BPH) patients are nowadays operated on at an older age, usually after they have received medical treatment for a long period of time. We correlated physical status classification indices (American Society of Anesthesiologists (ASA) and Goldman's) with the patients’ profiles and estimated, subjectively, the operative risk profile at the time of the first visit to a urologist for BPH-related lower urinary tract symptoms (LUTS).
Methods:
Fifty-six patients aged 51–84 years, scheduled for transurethral or open adenomatectomy, were included in the study. Physical status indices were correlated with patient and disease characteristics, as well as with the time from the first visit seeking advice for BPH-related LUTS to the final decision for surgical treatment. Anesthesiologists estimated whether the operative risk would have been lower if surgery had been offered as a first line treatment option.
Results:
ASA and Goldman's indices did not correlate with patient and disease characteristics except for the correlations of the ASA index with comorbidity and with time from first visit, and Goldman's index with age. Subjects in whom the decision for surgery was delayed for more than 1 year from initial visit had significantly higher International Prostate Symptom Scores (IPSS) at surgery, and they also had a higher ASA index and acute urinary retention rate. In 12 cases (21.4%) anesthesiologists estimated that operative risk would have been less if surgery had been performed at the time of the first visit, with the probability of a hypothetical change in operative risk profile correlating only with the length of time of LUTS and concomitant cardiovascular or chronic obstructive pulmonary disease.
Conclusions:
As the impact of medical treatment for LUTS/BPH will probably further increase over the coming years, patients at risk of developing complications needing surgery should be estimated for a possible future deterioration of their physical status and be advised accordingly.
Get full access to this article
View all access options for this article.
References
1.
VerhammeK.M.C., DielemanJ.P., BleuminkG.S., et al.Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care – The Triumph Project. Eur Urol, 2002; 42:323–328.
2.
MadersbacherS., HaidingerG., TemmlC., SchmidbauerC.P.Prevalence of lower urinary tract symptoms in Austria as assessed by an open survey of 2,096 men. Eur Urol, 1998; 34:136–141.
3.
LundB.L., DingsorE.Benign obstructive prostatic enlargement. A comparison between the results of treatment by transurethral electro-resection and the results of open surgery. Scand J Urol Nephrol, 1976; 10:33–38.
4.
DollH.A., BlackN.A., McPhersonK., FloodA.B., WilliamsG.B., SmithJ.C.Mortality, morbidity and complications following transurethral resection of the prostate for benign prostatic hypertrophy. J Urol, 1992; 147:1566–1573.
5.
FourcadeR.O., LansonY., TeillacP.Results of the surgical treatment of benign hypertrophy of the prostate. Progrès en Urologie, 1993; 3:823–915.
6.
TubaroA., CarterS., HindA., VicentiniC., MianoL.A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia. J Urol, 2001; 166:172–176.
7.
HoltgreweH.L., Bay-NielsenH., CarlssonP., et al.The economics of the management of lower urinary tract symptoms and benign prostatic hyperplasia. In: DenisL., GriffithsK., KhouryS., CockettA.T.K., McConnellJ., ChatelainC., MurphyG., YoshidaO., editors. Proceedings of the 4th International Consultation on Benign Prostatic Hyperplasia (BPH). Plymouth: Plymbridge Distributors Ltd; 1998. p. 63–81.
8.
WilsonJ.R., UrwinG.H., StowerM.J.The changing practice of transurethral prostatectomy: a comparison of cases performed in 1990 and 2000. Ann R Coll Surg Engl, 2004; 86:428–431.
9.
MadersbacherS., AlivizatosG., NordlingJ., SanzC.R., EmbertonM., de la RosetteJ.J.EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol, 2004; 46:547–554.
10.
McNicholasT.A.Lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the current practice patterns?. Eur Urol, 2001; 39(suppl. 3):26–30.
11.
VerhammeK.M.C., DielemanJ.P., BleuminkG.S., BoschJ.L.H.R., StrickerB.H.C., SturkenboomM.C.J.M.Treatment strategies, patterns of drug use and treatment discontinuation in men with LUTS suggestive of benign prostatic hyperplasia: the Triumph project. Eur Urol, 2003; 44:539–545.
12.
Lu-YaoG.L., BarryM.J., ChangC.H., WassonJ.H., WennbergJ.E.Transurethral resection of the prostate among Medicare beneficiaries in the United States: time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology, 1994; 44:692–698.
13.
BoyleP.Some remarks on the epidemiology of acute urinary retention. Archivio Italiano di Urologia. Andrologia, 1998; 70:77–82.
14.
CliffordG.M., LogieJ., FarmerR.D.How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol, 2000; 38(suppl. 1):48–53.
15.
AndersonJ.B., RoehrbornC.G., SchalkenJ.A., EmbertonM.The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol, 2001; 39:390–399.
16.
EmbertonM., AndrioleG.L., de la RosetteJ., DjavanB., HoefnerK., Vela NavarreteR., et al.Benign prostatic hyperplasia: a progressive disease of aging men. Urology, 2003; 61:267–273.
17.
BarryM.J., FowlerF.J.Jr., BinL., PittsJ.C.3rd, HarrisC.J., MulleyA.G.Jr.The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol, 1997; 157:10–14.
18.
JacobsenS.J., JacobsonD.J., GirmanC.J., et al.Natural history of prostatism: risk factors for acute urinary retention. J Urol, 1997; 158:481–487.
19.
KawakamiJ., NickelJ.C.Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Canad J Urol, 1999; 6:819–822.
20.
HammarstenJ., HogstedtB.Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press, 1999; 8:29–36.
GoldmanL., CalderaD.L., NussbaumS.R., et al.Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med, 1977; 297:845–850.
23.
BlomqvistP., EkbomA., CarlssonP., AhlstrandC., JohanssonJ.-E.Benign prostatic hyperplasia in Sweden 1987–94: Changing patterns of treatment, changing pattern of costs. Urology, 1997; 50:214–219.
24.
XiaZ., RobertsR.O., SchottenfeldD., LieberM.M., JacobsenS.J.Trends in prostatectomy for benign prostatic hyperplasia among black and white men in the United States: 1980 to 1994. Urology, 1999; 53:1154–1159.
25.
WassonJ.H., BubolzT.A., Lu-YaoG.L., Walker-CorkerE., HammondC.S., BarryM.J.for the Patient Outcomes Research Team for Prostatic Diseases. Transurethral resection of the prostate among Medicare beneficiaries: 1984 to 1997. J Urol, 2000; 164:1212–1215.
26.
WeiJ.T., CalhounE., JacobsenS.J.Urologic diseases in America project: benign prostatic hyperplasia. J Urol, 2005; 173:1256–1261.
27.
BorthC.S., BeikoD.T., NickelJ.C.Impact of medical therapy on transurethral resection of the prostate: a decade of change. Urology, 2001; 57:1082–1086.
28.
WyattM.G., StowerM.J., SmithP.J., RobertsJ.B.Prostatectomy in the over 80-year-old. Br J Urol, 1989; 64:417–419.
29.
KroghJ., JensenJ.S., IversenH.G., AndersenJ.T.Age as a prognostic variable in patients undergoing transurethral prostatectomy. Scand J Urol Nephrol, 1993; 27:225–229.
30.
IlkjaerL.B., LundL., NielsenK.T.Outcome of transurethral prostatectomy in men over 80 years. Scand J Urol Nephrol, 1998; 32:270–272.
31.
NaduA., MabjeeshN.J., Ben-ChaimJ., KaverI., MatzkinH., GreensteinA.Are indications for prostatectomy in octogenarians the same as for younger men?. Int Urol Nephrol, 2004; 36:47–50.
32.
Vela NavarreteR., Gonzalez EnguitaC., Garcia CardosoJ.V., ManzarbeitiaF., Sarasa-CorralJ.L., GranizoJ.J.The impact of medical therapy on surgery for benign prostatic hyperplasia: a study comparing changes in a decade (1992–2002). BJU Int, 2005; 96:1045–1048.
33.
SandfeldtL., HahnR.G.Cardiovascular risk factors correlate with prostate size in men with bladder outlet obstruction. BJU Int, 2003; 92:64–68.
34.
ReidB.C., AlbergA.J., KlassenA.C., KochW.M., SametJ.M.The American Society of Anesthesiologists’ class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck, 2001; 23:985–994.
35.
FroehnerM., KochR., LitzR., et al.Preoperative cardiopulmonary risk assessment as predictor of early noncancer and overall mortality after radical prostatectomy. Urology, 2003; 61:596–600.
36.
DjavanB., FongY.K., HarikM., et al.A longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology, 2004; 64:1144–1148.
37.
LeeA.J., GarrawayW.M., SimpsonR.J., FisherW., KingD.The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol, 1998; 34:325–332.
38.
McConnellJ.D., RoehrbornC.G., BautistaO.M., et al.for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med, 2003; 349:2387–2451.
39.
RalfK., TunnU., RennebergH., SengeT., HauptG.Influence of age on postoperative outcome and complication rates in 1857 patients undergoing transurethral resection of the prostate (TURP). Eur Urol, 2000; 37(suppl. 2):42 [Abstract].
40.
FongY.K., MilaniS., DjavanB.Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol, 2005; 15:35–38.
